Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 475207-59-1 | Product Number: N1229
Sorafenib Tosylate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- 4-[4-[3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy]-N-methylpicolinamide 4-Methylbenzenesulfonate
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamamido]phenoxy]-N-methyl-2-pyridinecarboxamide 4-Methylbenzenesulfonate
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 1G |
$81.00
|
Contact Us | Contact Us | 36 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | N1229 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__1__6ClF__3N__4O__3.C__7H__8O__3S = 637.03 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 475207-59-1 |
| Reaxys Registry Number | 11116227 |
| MDL Number | MFCD08235032 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 222.0 to 226.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 224 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | US4588880 |
Transport Information:
| HS Number | 2933.39.6191 |
Application
Sorafenib Tosylate: An Orally Active Multikinase Inhibitor
Sorafenib tosylate (BAY 43-9006) is an orally active multikinase inhibitor that decrease tumor cell proliferation. There are reports that sorafenib is shown to inhibits cell surface tyrosine kinase receptors (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß: platelet-derived growth factor receptor-β) and downstream intracellular serine/threonine kinases (c-CRAF, BRAF and mutant BRAF) in vitro.1-3) Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis.4,5) In clinical, sorafenib tosylate is used for the treatment of renal cell carcinoma and hepatocellular carcinoma. (The product is for research purpose only.)
References
- 1) BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- 2) Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
- 3) BAY 43-9006 Inhibition of Oncogenic RET Mutants
- F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, M. Santoro, J. Natl. Cancer Inst. 2006, 98, 326.
- 4) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (a review)
- 5) Sorafenib: a review of its use in advanced hepatocellular carcinoma
- 6) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.